Stellar Biotechnologies revenues $0.21 millionStaff Writer |
Stellar Biotechnologies Net loss was $5.04 million
Stellar Biotechnologies reported financial results for the fiscal year ended September 30, 2018.
For fiscal year 2018, Stellar reported a net loss of $5.04 million, or $1.76 per basic share, compared to a net loss of $5.03 million, or $3.44 per basic share, for fiscal year 2017.
The weighted average number of shares used in the calculation of net loss per share for fiscal years 2018 and 2017 were 2,869,374 and 1,462,459, respectively.
At September 30, 2018, the company had working capital of $10.2 million. Cash, cash equivalents and short-term investments totaled $10.3 million. ■
What to read next